Clinical Trials
346
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (300 trials with phase data)• Click on a phase to view related trials
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
- Conditions
- Solid CancersRadiotherapyImmune Checkpoint InhibitorLung Cancer
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT07058948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Drug: fractionated liposomal irinotecan (II)-based combination chemotherapy (FOLFIRInali-3) plus bevacizumab (Bev)
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Target Recruit Count
- 46
- Registration Number
- NCT07047560
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Target Recruit Count
- 52
- Registration Number
- NCT07038629
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China
A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer
- Conditions
- HER2 OverexpressionAdvanced Stage Breast CancerLow Expression of HER2
- Interventions
- Drug: T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Target Recruit Count
- 200
- Registration Number
- NCT07035353
Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer
- Conditions
- Gastric Cance
- Interventions
- Drug: Adebrelimab+SOX
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Target Recruit Count
- 40
- Registration Number
- NCT07033143
- Prev
- 1
- 2
- 3
- 4
- 5
- 70
- Next
News
Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial
A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.
Phase 2 Trial Shows Promise: Camrelizumab Plus Chemotherapy Effective for Advanced Nasopharyngeal Cancer in Non-Endemic Regions
A phase 2 trial demonstrates that combining camrelizumab immunotherapy with induction chemotherapy and chemoradiotherapy achieved an 84% 3-year disease-free survival rate in advanced nasopharyngeal cancer patients.
Pyrotinib Plus Metronomic Vinorelbine Shows Efficacy in HER2+ Advanced Breast Cancer Post-Trastuzumab
A phase 2 trial in China demonstrated that pyrotinib combined with metronomic vinorelbine is effective in HER2-positive advanced breast cancer patients after trastuzumab failure.